Dunfu Medical Secures RMB 100 Million Series A Funding Led by New Frontier, Accelerating Its 'One Core, Two Wings' Oncology Healthcare Ecosystem

VCBeat has learned that Shanghai Dunfu Medical Management Group Co., Ltd. (hereinafter referred to as “Dunfu Medical”) recently completed a Series A financing round amounting to hundreds of millions of RMB. This round was jointly funded by New Frontier Health, Smartgain Capital, and other investors.

Upon completion of this round of financing, Shanghai Dunfu Hospital, under Dunfu Medical, will complete its Phase II expansion, while the Tianjin and Guangzhou campuses of Dunfu Medical will be established. Building on its earlier development, Dunfu Medical has established a specialized management platform for multiple tumor types and is driving the large-scale operationalization of oncology data.

Dunfu Medical has established a “one core, two wings” architecture comprising a chain of specialized oncology hospitals, a disease-specific management platform, and oncology data services.

Dunfu Medical established its group company in March 2020, with core businesses encompassing the development and operation of a chain of specialized oncology hospitals, multi-disease specialty management for cancer patients, and oncology data operations, thereby building a comprehensive oncology ecosystem. Drawing extensively on mature international best practices and aligning with the current supply and demand dynamics of leading public oncology healthcare services in China, the company closely collaborates with the top five public oncology hospitals (centers) nationwide. It focuses on patients’ actual needs to establish compliant healthcare service scenarios outside public hospitals.

Since the outbreak of the pandemic in 2020, Shanghai Dunfu Hospital, operated by Dunfu Medical, has achieved continuous breakthroughs in patient volume and medical services. Meanwhile, this model is being further optimized for replication and implementation at Tianjin Dunfu (trial operations began in March) and Guangzhou Dunfu (trial operations began in May). Upon the completion of this round of financing, Dunfu Medical has initially established an offline specialized development framework, replicating three standardized hospital campuses in Shanghai, Tianjin, and Guangzhou—three cities with core national oncology medical resources. The company will continue to plan its expansion into cities such as Beijing, further solidifying Dunfu Medical’s core foundation and resources.

Shanghai Dunfu Hospital, located in the core urban area of Shanghai and operating under Dunfu Medical, has established itself as a model hospital offering integrated pre-diagnostic, diagnostic, and post-diagnostic oncology services. As a member of the specialized medical consortium affiliated with Fudan University Shanghai Cancer Center, the hospital features distinctive capabilities in “precision cancer screening and triage, application of novel oncology drugs and technologies, perioperative supportive care, and oncology rehabilitation.” By 2021, it had cumulatively served nearly 50,000 patient visits, providing services such as cancer indication screening, PD-1/PD-L1 therapy, and rehabilitation management for cancer patients, earning a strong reputation among oncology patients in the Yangtze River Delta region.

Concurrently with the announcement of this round of financing, Dunfu Medical also announced two completed mergers and acquisitions:

1) Completed the acquisition of Ruochu Health, a well-known breast cancer patient management platform in China.Ms. Jiang Qin, founder of Ruochu Health, will assume the role of Director of the Oncology Ecosystem Operations Center at Dunfu Medical, while continuing to oversee Ruochu Health’s existing operations. Following the integration of Ms. Jiang’s team, Dunfu Medical will expand its workforce and further invest in disease-specific patient management for oncology and other oncology ecosystem initiatives, building upon Ruochu Health’s established breast cancer specialty care management services. The company will also strengthen its collaborative engagements with pharmaceutical companies and hospitals, and upgrade its intelligent internet-based patient management platform. These efforts will elevate Dunfu Medical’s capabilities in offline chain operations, patient acquisition channels, multi-disease management, and synergistic interactions within the oncology ecosystem, thereby advancing the construction of a “Responsible Oncology Healthcare Ecosystem” and delivering sustainable corporate value and social responsibility.

2) Completed the acquisition of "Guangzhou Bodé Jialian Outpatient Department" under New Frontier Health.The new Guangzhou Dunfu Medical Clinic will serve as one of the core pillars of Dunfu Medical’s presence in Guangzhou, integrating proven business models to actively innovate and expand into the South China market, while staying true to its original mission of serving more cancer patients.

Mr. Zhuo Guangsong, CEO of Dunfu Medicalindicates: During my previous experience in investing in the healthcare and wellness sector, I placed significant emphasis on medical service business models that prioritize patient needs, serve public hospitals, experts, and pharmaceutical companies, while simultaneously achieving synchronized growth in both business value and capital value.

Capital circles continue to intensify their investments in innovative cancer therapies, novel drugs, and oncology healthcare services. These sectors are gradually reaching a stage of fruition, thereby improving the average survival rates and life expectancy for malignant tumor patients both in China and globally. While the incidence of various types of malignant tumors in China continues to rise, the number of licensed oncology hospitals and hospital beds nationwide has grown slowly over the years. We observe that cancer diagnosis and screening behaviors remain relatively passive, core diagnostic and treatment processes are congested and urgently require efficiency improvements, and opportunities are emerging in the post-hospital rehabilitation market. Furthermore, we have initially explored an innovative business model that effectively links public and private oncology medical institutions, providing patients with a service chain encompassing early screening, early diagnosis, early treatment, and long-tail specialized rehabilitation after surgery. Simply summarized using a model: ∑ (Medical Capability + Innovative Model) × Intensity of Technology Adoption = Benefit Growth.

From its inception, Dunfu Medical Group has integrated strategic vision, pragmatic operations, and a capital-oriented mindset. After two years of strategic refinement and business integration, we have firmly established Dunfu’s “ecological niche” within an ecosystem comprising public hospitals, medical experts, patients, pharmaceutical companies, and payers. We extend our sincere gratitude to Mr. Wu Qinan and the New Frontier Health team for their recognition, and to Mr. Deng Qiang and the Smartgain Capital team for their deep involvement. All investors in this round will provide substantial empowerment to Dunfu Medical, contributing additional resources and expertise to the development of our “Responsible Oncology Care Ecosystem.” The company remains committed to adopting a more pragmatic, proactive, and rigorous approach to delivering higher-quality medical services to cancer patients.

New Frontier Health Group, the lead investor in this round, is a renowned medical industry operations and investment group in China. It holds controlling interests in and operates multiple leading domestic healthcare brands, including United Family Healthcare, Glodon Medical, Yidekang Medical, Xiyu Medical, Baitai Health Insurance Services, New Frontier Technology, and New Frontier Capital.

Smartgain Capital is an emerging family office focused on growth-stage investment opportunities in the healthcare, technology, and consumer sectors. The management team has participated in numerous investments in these fields, including: Smart Health, AiHuiShou (ATRenew), Crown Bioscience, Meiyou, Kyee Technology, Zongmu Technology, A1 Snack Lab, FineEx, and Wosi Technology, demonstrating profound research and insights into medical services and chronic disease management.